Institution statistics

GLAXOSMITHKLINE BIOLOGICALS SA - Belgium 

Ranking results:

Past rankings:
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2010
Criterium:Position:
Overall Score:900-1000
Total Project Funding:700-800
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:800-900
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:> 1000
Total Project Funding:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding:200-300
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000
Networking Rank (Reputation):800-900
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
Ranking timeline:

European project participation (2000-01-01 - 2019-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 23
As coordinator: 5
As participant: 15
Sole participant: 3
Coordinator / Participant Ratio: 0.33*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2019 0 5.499.882 0 1
2017 0 25.810.243 0 3
2016 0 28.850.000 0 2
2015 0 18.200.000 0 1
2014 21.153.216 0 17.375.837 2
2013 339.600 10.313.706 1.151.600 2 2
2011 0 29.980.670 0 1
2010 220.500 11.996.730 370.500 1 1
2007 0 20.095.505 515.269 1
2006 5.499.324 7.997.720 1.212.766 1 1
2004 0 17.000.000 485.714 1
2002 1.062.554 1.462.733 516.711 1 1
2000 2.640.000 0 293.333 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD9
INSTITUT PASTEUR7
ISTITUTO SUPERIORE DI SANITA7
SANOFI PASTEUR7
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE6
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE6
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE6
STATENS SERUM INSTITUT6
DEPARTMENT OF HEALTH5
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV5
ACADEMISCH ZIEKENHUIS LEIDEN4
MEDICAL RESEARCH COUNCIL4
NATIONAL BIOLOGICAL STANDARDS BOARD4
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU4
UNIVERSITE LIBRE DE BRUXELLES4
ACADEMISCH ZIEKENHUIS GRONINGEN3
ASTON UNIVERSITY3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE3
HEALTH PROTECTION AGENCY3
INSTITUT PASTEUR DE LILLE3
INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE3
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE3
PFIZER LIMITED3
ST GEORGE'S HOSPITAL MEDICAL SCHOOL3
STICHTING TUBERCULOSIS VACCINE INITIATIVE3
UNIVERSITAET INNSBRUCK3
UNIVERSITAIR MEDISCH CENTRUM UTRECHT3
UNIVERSITE DE GENEVE3
ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE2
ASTRAZENECA AB2
BIOMERIEUX2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
EDUCATIONAL FOUNDATION YONSEI UNIVERSITY2
FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA2
FUNDACIO INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL2
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA2
HOOKIPA BIOTECH2
HOSPICES CANTONAUX CHUV2
KAROLINSKA INSTITUTE2
KING'S COLLEGE LONDON2
LEIDEN UNIVERSITY MEDICAL CENTER2
MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT2
P95 CVBA2
STICHTING KATHOLIEKE UNIVERSITEIT2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
UNIVERSIDAD DE ZARAGOZA2
UNIVERSITA DEGLI STUDI DI SIENA2
UNIVERSITAET ULM2
UNIVERSITAET ZUERICH2
UNIVERSITEIT ANTWERPEN2
UNIVERSITEIT GENT2
UNIVERSITEIT UTRECHT2
UNIVERSITY COLLEGE LONDON2
UNIVERSITY OF CAPE TOWN2
UNIVERSITY OF SURREY2
ABBOTT BIOLOGICALS BV1
ABERA BIOSCIENCE AB1
ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM1
AERAS GLOBAL TB VACCINE FOUNDATION1
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN1
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRL ALTA1
ALTA S P A1
APITOPE INTERNATIONAL NV1
APLAGEN1
ARENAVAX1
ARMAUER HANSEN RESEARCH INSTITUTE1
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1
AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY1
AVENTIS PASTEUR1
AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO1
BACHEM FEINCHEMIKALIEN AG@@@1
bangor university1
BERNHARD NOCHT INSTITUT FUER TROPENMEDIZIN1
BIONEEDLE TECHNOLOGIES GROUP BV1
BOEHRINGER INGELHEIM VETMEDICA1
BORD OSPIDEIL NAOIMH SHEAMUIS1
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL1
CENTRE FOR RESEARCH AND TECHNOLOGY HELLAS1
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS1
CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH POLSKIEJ AKADEMII NAUK1
CHALMERS TEKNISKA HOEGSKOLA AKTIEBOLAG1
CHIRON S R L1
COMMISSION OF THE EUROPEAN COMMUNITIES DIRECTORATE GENERAL JOINT RESEARCH CENTRE JRC1
CONFEDERATION OF MENINGITIS ORGANISATIONS1
CROSSBETA BIOSCIENCES BV1
DA VOLTERRA SAS1
DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E V1
DEUTSCHES PRIMATENZENTRUM1
DEUTSCHES WOLLFORSCHUNGSINSTITUT AN DER RWTH AACHEN E V1
DUOTOL AB1
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE1
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH1
EMORY UNIVERSITY NON PROFIT CORP1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE1
EUROPEAN AIDS TREATMENT GROUP EV1
EUROPEAN VACCINE INITIATIVE EWIV1
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES1
FOLKEHELSEINSTITUTTET1
Constancy:

Total number of partners:375

Partner loyalty:
Frequent Partner: (> 2 projects): 126
Rare Partner: 249

Frequent / Rare Partner Ratio: 0.51

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES13
RTD HORIZONTAL TOPICS8
SOCIAL AND ECONOMIC CONCERNS4
PROTECTING MAN AND HIS ENVIRON3
INDUSTRY AND TECHNOLOGY1

Project overview:

Start dateProjectacronymrolefundingpartners
2019-01-01Vaccines and Infectious Diseases in the Ageing PopuLation VITALparticipant5.499.88224
2017-11-01Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections COMBACTE-CDIparticipant2.312.30514
2017-07-01Development of Robust and Innovative Vaccine Effectiveness DRIVEparticipant8.999.81315
2017-01-01REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 RESCEUparticipant14.498.12518
2016-03-01Vaccine lot to Vaccine lot comparison by consistancy testing - Sofia ref.: 115924 VAC2VACparticipant7.850.00023
2016-03-01PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 PERISCOPEparticipant21.000.00024
2015-01-01TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development TBVAC2020participant18.200.00044
2014-10-07Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine EbolaVaccoordinator15.153.2164
2014-02-01"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" EXALTcoordinator6.000.0005
2013-12-01"The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease." DAVIADparticipant5.924.8934
2013-07-01Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses ADJSYNcoordinator169.8001
2013-05-01Exploring the roles and plasticity of T-cell responses in anti-BACterial immunity T-BACcoordinator169.8001
2013-02-01Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens PEACHIparticipant4.388.8135
2011-10-01Advanced Immunization Technologies ADITECparticipant29.980.67052
2010-06-02System for Immunological Modelling as an Ultimate tool to Link Adjuvant function To Adaptive immune responses SIMULATAcoordinator220.5001
2010-01-01Discovery and preclinical development of new generation tuberculosis vaccines NEWTBVACparticipant11.996.73035
2007-01-01European vaccine and microbicides enterprise EUROPRISEparticipant20.095.50539
2006-10-01Nanoscale Functionalities for Targeted Drug Delivery of Biopharmaceutics NANOBIOPHARMACEUTICSparticipant7.997.72027
2006-01-01Recombinant measles virus as a vector for HIV vaccines RMVHIVcoordinator5.499.3246
2004-01-01An Integrated project for the design and testing of vaccine candidates against tuberculosis: Identification, development and clinical studies TB-VACparticipant17.000.00035
2002-11-01Improvement of a therapeutic adjuvanted protein hiv vaccine by combination with dna immunization in prime-boost regimen (HIVPRIMEBOOSTTHERVAC) HIVPRIMEBOOSTTHERVACcoordinator1.062.5543
2002-01-01Phase-i and ii trials of the malaria pre-erythrocytic vaccine lsa-3 and refinement of measurable outcomes (EMLI) EMLIparticipant1.462.7339
2000-02-01A new vaccine strategy against serogroup b meningococcal infection: from antigen discovery to clinical trials MENB VACCINEcoordinator2.640.0009

Alias institution names:
  • GLAXOSMITHKLINE BIOLOGICALS

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum